Letters
Respiratory disease Environmental health Toxicology
Volume 216 - Issue 7

E‐cigarette or vaping product use‐associated lung injury in an adolescent

Authors:  Betty SH Chan, Vicky Sheppeard and Andrew H Dawson

Med J Aust 2022; 216 (7): 374-374. || doi: 10.5694/mja2.51473
Published online: 18 April 2022

In reply

Download PDF (148 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

In reply: We thank McKenzie and colleagues1 for their interest in our article.2 We reported the case of a 15‐year‐old girl with the diagnosis of e‐cigarette or vaping product use‐associated lung injury (EVALI) who admitted to a 7‐month history of vaping nicotine and presented with acute lung injury. She had an extensive negative microbiological and vascular screen. We would dispute the suggestion that this patient had an underlying urosepsis resulting in acute lung injury. Even though this patient reported dysuria and urinary frequency, the urine analysis was negative for nitrites and leukocytes. In addition, urine and blood culture were sent before the administration of antibiotic therapy and the results were negative. Although dysuria can be caused by infection, it can also be caused by vaginitis, urethritis, or a non‐infectious cause such as inflammation.3 While there are reported incidences of urosepsis resulting in acute lung injury, they were usually associated with oliguria, acute kidney injury and septic shock. This patient had normal renal function (creatinine level, 66 μmol/L) and blood pressure and did not require inotropic support during her hospital admission. Therefore, the proposed alternative diagnosis of urosepsis cannot be upheld.

Vitamin E acetate and tetrahydrocannabinoids‐containing vaping products are implicated in the pathogenesis of EVALI, yet 15% of patients with this diagnosis report using only nicotine‐containing products.4 Hence, no specific chemicals have been identified conclusively to date as the cause of the acute lung injury.5

 

Authors

  • Betty SH Chan1
  • Vicky Sheppeard2
  • Andrew H Dawson3,4
  • 1. Prince of Wales Hospital and Community Health Services, Sydney, NSW
  • 2. NSW Health, Sydney, NSW
  • 3. Royal Prince Alfred Hospital, Sydney, NSW
  • 4. New South Wales Poisons Information Centre, Children’s Hospital at Westmead, Sydney, NSW

Correspondence: betty.chan1@health.nsw.gov.au

Competing interests

No relevant disclosures.

References

Linked content

  • MJA Lessons from Practice: E‐cigarette or vaping product use‐associated lung injury in an adolescent

  • MJA Letter: E‐cigarette or vaping product use‐associated lung injury in an adolescent

View this article on Wiley Online Library

More like this

Respiratory disease Research 18 August 2026 Open Access

Uneven Ground: Survival Differences Among Victorian Lung Cancer Patients by Location of Residence (2011–2023): A Retrospective Cohort Study

Evangeline Samuel, Eldho Paul, Mike Lloyd, Sanuki Tissera, Craig Underhill, Sagun Parakh, Phillip Parente, Inger Olesen, Javier Torres, Katharine See, Gavin M. Wright, David Langton, Thomas John, Matthew Conron, James Bartlett, Nicola Atkin, Nikolajs Zeps, Susan V. Harden, Wasek Faisal, John R. Zalcberg, Rob G. Stirling

Respiratory disease Research 28 June 2026 Free

Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study

Melanie Wong, Mike Lloyd, Jessie Zeng, Sanuki Tissera, Kalinda E. Griffiths, Justine Clark, Jonathan Gillies, Lisa Briggs, Jacqueline Lesage, Tom Wood, Craig Underhill, Sagun Parakh, Louis B. Irving, Wasek Faisal, Rob Blum, Gary E. Richardson, Phillip Parente, Michelle Caldecott, Inger Olesen, Javier Torres, Evangeline Samuel, Christopher Lyne, Katharine See, David Langton, Thomas John, Gavin Wright, Matthew Conron, James Bartlett, Golsa Adabi, Maggie Moore, Susan Harden, Zoe K. McQuilten, John R. Zalcberg, Rob Stirling

View more